This trend is consistent with data from other studies showing a correlation between high CD47 expression and worse clinical outcome in several malignancies including acute myeloid leukemia, gastric cancer and ovarian cancer.36, 37, 38 Given the high expression of CD47 in our study cohort and based on the promising findings from preclinical SCLC models underlining the potency of anti-CD47 therapy in vivo, further studies are warranted to evaluate CD47 as a promising target in SCLC.17 This evidence concerns the gene CD47 and ovarian carcinoma.